While the CEO of Transgene aspires to launch their product independently in Europe, he acknowledges the immense cost of a Phase 3 trial. A partnership with a large pharmaceutical company is viewed as the most realistic "best case scenario" to accelerate development and de-risk the final, most expensive stage.

The company's long-term plan is to handle drug development through to a successful New Drug Application (NDA) filing, then partner with a larger pharmaceutical company for marketing and sales. By deliberately avoiding the need to build a commercial sales force, they maintain focus on their core competency: drug development and clinical execution.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

Zevra accelerated its transition to a commercial-stage company by acquiring Acer Therapeutics. This strategic move provided a foundational commercial team, specialty pharmacy contracts, and patient advocacy relationships, de-risking their upcoming drug launch by avoiding the distraction of building it all from scratch.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

The Most Favored Nation (MFN) policy forces a difficult choice: launch early in Europe and risk a lower US reference price, or delay the European launch to protect US revenue, slowing patient access. This dilemma upends traditional global launch strategies, creating commercial, ethical, and operational problems for pharma companies.

Unlike typical biotechs that grow from Research to Development to Commercial (R-D-C), Zevra is pursuing a 'C to D to R' model. It focuses first on executing commercially and in late-stage development, using that success to become a partner of choice and eventually earn the right to invest in early-stage research.

The FDA is predicted to approve new PARP inhibitors from trials like AMPLITUDE only for BRCA-mutated patients, restricting use to where data is strongest. This contrasts with the EMA's potential for broader approvals or denials. This highlights the diverging regulatory philosophies that create different drug access landscapes in the US and Europe.

Zevra's CEO argues that while regulatory frameworks have built-in flexibility for rare diseases, the inconsistent application of these rules is the biggest challenge. This uncertainty makes it difficult for companies to know if their development plan and data package will meet the bar for approval upon review.